# A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

> **NCT06378177** · PHASE2 · RECRUITING · sponsor: **Lyvgen Biopharma Holdings Limited** · enrollment: 64 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **BIOLOGICAL:** LVGN6051 Monoclonal Antibody Injection
- **BIOLOGICAL:** toripalimab Injection
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT06378177
- **Lead sponsor:** Lyvgen Biopharma Holdings Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-21
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2024-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06378177

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06378177, "A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06378177. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*